Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.6M Buy
950,460
+249,969
+36% +$3.18M 0.05% 313
2025
Q4
$11.5M Buy
+700,491
New +$10.9M 0.05% 309
2025
Q1
$17.3M Buy
1,683,956
+253,141
+18% +$3.26M 0.09% 202
2024
Q4
$18.2M Buy
1,430,815
+878,352
+159% +$11.6M 0.09% 221
2024
Q3
$7.07M Sell
552,463
-1,838,981
-77% -$22.5M 0.03% 406
2024
Q2
$30.3M Sell
2,391,444
-68,720
-3% -$1.19M 0.15% 130
2024
Q1
$55.8M Buy
2,460,164
+267,545
+12% +$6.26M 0.28% 88
2023
Q4
$54.5M Buy
2,192,619
+627,634
+40% +$12.3M 0.28% 90
2023
Q3
$26.8M Buy
1,564,985
+1,518,592
+3,273% +$25.3M 0.15% 142
2023
Q2
$815K Hold
46,393
﹤0.01% 705
2023
Q1
$815K Buy
+46,393
New +$701K ﹤0.01% 707

Other funds holding PATH

Glenmede Trust's PATH Position: Q1 2026 in Review

Glenmede Trust increased its UiPath (PATH) stake by 36% in Q1 2026, buying an estimated $3.18M and bringing the position to 950,460 shares worth $10.6M. The position accounts for 0.05% of the portfolio, ranked #313.

Glenmede Trust first reported a position in PATH in Q1 2023 and has held it in 11 quarters since. The position peaked at $55.8M in Q1 2024. 533 funds tracked by Wall St. Rank hold PATH as of Q1 2026.

  • Glenmede Trust held 950,460 shares of UiPath worth $10.6M as of Q1 2026.
  • Glenmede Trust bought 249,969 UiPath shares in Q1 2026, an estimated $3.18M.
  • UiPath made up 0.05% of Glenmede Trust's portfolio in Q1 2026, its #313 holding.
  • Glenmede Trust first reported a position in UiPath in Q1 2023 and has held it in 11 quarters since.
  • Glenmede Trust's UiPath position peaked at $55.8M in Q1 2024.
  • 533 funds tracked by Wall St. Rank held UiPath as of Q1 2026.

Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.